Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$46.55 USD

46.55
10,291,144

+0.62 (1.35%)

Updated Aug 12, 2025 04:00 PM ET

After-Market: $46.54 -0.01 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (141 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..

Mark Vickery headshot

Top Analyst Reports for ExxonMobil, Disney & AbbVie

by Mark Vickery

Today's Research Daily features new research reports on 12 major stocks, including ExxonMobil (XOM), Disney (DIS), and AbbVie (ABBV).

    Zacks Equity Research

    Pfizer's (PFE) Lung Cancer Drug Vizimpro Gets FDA Approval

    by Zacks Equity Research

    The FDA approves Pfizer's (PFE) Vizimpro for first-line treatment of locally advanced or metastatic non-small cell lung cancer in patients with epidermal growth factor receptor activating mutations.

      Zacks Equity Research

      Women Health a Prime Concern Worldwide: 3 Stocks in Focus

      by Zacks Equity Research

      Women health care gradually gaining importance globally, investors might keep an eye on a few stocks.

        Kinjel Shah headshot

        Big Pharma Players on Strong Footing Ahead of Q4: 4 Picks

        by Kinjel Shah

        The large-cap pharma industry has been on a strong footing lately and looks well poised for Q4. Here are four stocks from the space that investors may consider betting on.

          Zacks Equity Research

          Top Ranked Income Stocks to Buy for September 27th

          by Zacks Equity Research

          Here are three stocks with buy rank and strong income characteristics for investors to consider today, September 27th:

            Zacks Equity Research

            Novartis to Cut Over 2000 Jobs, Focus on Higher Value Drugs

            by Zacks Equity Research

            Novartis (NVS) plans to lay off about 2000 jobs in Switzerland and the United Kingdom in order to focus on innovative, specialized and personalized medicines than on mass-produced products.

              Zacks Equity Research

              AstraZeneca's Imfinzi Gets EU Nod for Early-Stage Lung Cancer

              by Zacks Equity Research

              AstraZeneca's (AZN) PD-L1 inhibitor Imfinzi gets approval in EU for an early-stage lung cancer indication.

                Zacks Equity Research

                Why the Earnings Surprise Streak Could Continue for Bristol-Myers (BMY)

                by Zacks Equity Research

                Bristol-Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

                  Swarup Gupta headshot

                  Trump Clinches Trade Deal With South Korea: 6 Winning Picks

                  by Swarup Gupta

                  Trump claims that U.S. auto, pharma and agricultural products will gain from the deal with South Korea.

                    Zacks Equity Research

                    J&J's Esketamine Fails to Meet Endpoint in Phase III Study

                    by Zacks Equity Research

                    J&J's (JNJ) late-stage candidate, esketamine nasal spray, fails to show statistical significance for the primary endpoint in a phase III study on patients with treatment-resistant depression.

                      Zacks Equity Research

                      AbbVie/Roche's Leukemia Drugs Combo Gets CHMP Backing in EU

                      by Zacks Equity Research

                      The CHMP gives positive opinion for combination use of AbbVie's (ABBV) Venclexta and Roche's Rituxan for relapsed/refractory CLL in patients who have received at least one prior therapy.

                        Zacks Equity Research

                        AstraZeneca's Diabetes Treatment Reduces Cardiovascular Risk

                        by Zacks Equity Research

                        AstraZeneca's (AZN) Farxiga led to a statistical significant reduction in hospitalization for heart failure or CV death in a cardiovascular outcomes study.

                          Zacks Equity Research

                          Bristol-Myers' MM Drug Empliciti Application Validated by EMA

                          by Zacks Equity Research

                          Bristol-Myers' (BMY) application for multiple myeloma drug, Empliciti gets validated in Europe.

                            Zacks Equity Research

                            Is Bristol-Myers Squibb (BMY) a Great Dividend Play?

                            by Zacks Equity Research

                            Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.

                              Zacks Equity Research

                              Novo Nordisk to Restructure R&D Unit & Lay Off 400 Staff

                              by Zacks Equity Research

                              Novo Nordisk (NVO) plans to restructure and reallocate resources in its Research and Development organization and lay off 400 employees from the unit.

                                Zacks Equity Research

                                Aduro's Cancer Arm & Strong Collaborations Boost Growth

                                by Zacks Equity Research

                                Aduro focuses on a broad pipeline of novel immunotherapies, developed for treating various types of cancers. Its collaboration agreements with large pharma companies fetch in regular funds.

                                  Zacks Equity Research

                                  Bayer (BAYRY) Focuses on Acquisitions, Competition a Concern

                                  by Zacks Equity Research

                                  Bayer (BAYRY) focuses on acquisitions and deals in order to boost growth as well as portfolio.

                                    Zacks Equity Research

                                    Cytori's Chemotherapy Candidate Gets Orphan Drug Status

                                    by Zacks Equity Research

                                    Cytori Therapeutics' (CYTX) chemotherapy candidate, ATI-1123, gets orphan drug status from the FDA for small cell lung cancer.

                                      Zacks Equity Research

                                      Can Pfizer (PFE) Bank on Bavencio for Long-Term Growth?

                                      by Zacks Equity Research

                                      Pfizer's (PFE) latest anti-PD-L1 immunotherapy, Bavencio, is being touted as a significant long-term top-line driver for the company.

                                        Zacks Equity Research

                                        Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus

                                        by Zacks Equity Research

                                        Label expansion of Merck's (MRK) Keytruda and FDA approval of AstraZeneca's (AZN) leukemia drug grab headlines this week

                                          Zacks Equity Research

                                          Roche's Child Arthritis Drug's New Formulation Gets FDA Nod

                                          by Zacks Equity Research

                                          Roche (RHHBY) gets FDA approval for the subcutaneous formulation of Actemra for the treatment of active systemic juvenile idiopathic arthritis in patients aged two years or older.

                                            Zacks Equity Research

                                            Merck's Antibacterial Drug Succeeds in Label Expansion Study

                                            by Zacks Equity Research

                                            Merck's (MRK) label expansion study evaluating its antibacterial drug, Zerbaxa for two types of pneumonia infections meets primary endpoints.

                                              Ekta Bagri headshot

                                              Immunotherapy for NSCLC: 4 Large-Cap Pharma Stocks in Focus

                                              by Ekta Bagri

                                              Here we take a look at companies with approved immunotherapy therapies or pipeline candidates for the treatment of widely prevalent NSCLC.

                                                Zacks Equity Research

                                                Bristol-Myers (BMY) Reports Phase II Data on Psoriasis Drug

                                                by Zacks Equity Research

                                                Bristol-Myers Squibb (BMY) announces encouraging data from a phase II study on plaque psoriasis candidate.

                                                  Zacks Equity Research

                                                  The Zacks Analyst Blog Highlights: Salesforce, Bristol Meyers and AB Volvo

                                                  by Zacks Equity Research

                                                  The Zacks Analyst Blog Highlights: Salesforce, Bristol Meyers and AB Volvo